Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III,Open-label,Prospective,Two-armed,Multicenter Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

NCT00322218 is registered in ClinicalTrials.gov with Spectrum Pharmaceuticals, Inc as lead sponsor.

NCT NCT00322218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00322218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III,Open-label,Prospective,Two-armed,Multicenter Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
Lead sponsor
Spectrum Pharmaceuticals, Inc
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2006
Completion date
December 31, 2008
Enrollment
68 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, large cell, diffuse